RCTcompstud: The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy

Sponsor
Kasr El Aini Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04244097
Collaborator
(none)
56
1
2
3.9
14.4

Study Details

Study Description

Brief Summary

Injection of intraperitoneal bupivacaine revealed an analgesic effect whether injected alone or in combination with other adjuvants, which increase duration of analgesia and decrease the dose of administered bupivacaine thus minimizing its side effects e.g. Opioids, Corticosteroids and Magnesium sulphate.

Neostigmine, a cholinesterase inhibitor that produces muscarinic receptor-mediated analgesia, increased postoperative analgesia when combined with local anaesthetics. Peripheral afferent nerve fibres contain muscarinic receptors, these could be a good target for pain suppression.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

The use of neostigmine as adjuvant to intraperitoneal bupivacaine was not previously investigated. In this study the investigators will compare the analgesic effect of bupivacaine alone and bupivacaine in combination with neostigmine when injected intraperitoneal in patients undergoing laparoscopic cholecystectomy.

Study Design

Study Type:
Interventional
Actual Enrollment :
56 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution. Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution. Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
Masking:
Single (Care Provider)
Masking Description:
Patients will be randomly allocated to one of two groups with the help of computer generated random number tables in opaque sealed envelopes prepared by an anaesthesiologist not part of the study. The envelops will be opened by the staff nurse, and peritoneal solution will be prepared according to group allocation by anaesthesiologist who is not involved in the study.
Primary Purpose:
Treatment
Official Title:
The Evaluation of the Analgesic Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Postoperative Pain in Laparoscopic Cholecystectomy:A Prospective, Randomized, Comparative, Double-blind Study.
Actual Study Start Date :
Apr 10, 2020
Actual Primary Completion Date :
Jul 6, 2020
Actual Study Completion Date :
Aug 6, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: B group

-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.

Drug: Bupivacaine Hydrochloride
after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Other Names:
  • Marcaine
  • Active Comparator: BN group

    Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.

    Drug: Bupivacaine Hydrochloride
    after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
    Other Names:
  • Marcaine
  • Drug: Neostigmine
    after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
    Other Names:
  • prostigmin
  • Outcome Measures

    Primary Outcome Measures

    1. Time of first analgesic requirements (in hours) after extubation [24 Hours post-operatively.]

      hours

    Secondary Outcome Measures

    1. • Total dose of intravenous pethidine (mg/24 hours). [24 hours]

      milligram

    2. • The use of intra-operative rescue analgesia. [intraoperative period]

      milligram

    3. • The severity of post-operative shoulder pain assessed by visual analogue scale [24 Hours post-operatively.]

      segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain 0 (no pain), 10(worst pain). The common format is a horizontal bar or line

    4. • The severity of post-operative abdominal pain assessed by visual analogue scale [24 hours posoperatively]

      segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain 0 (no pain), 10(worst pain). The common format is a horizontal bar or line

    5. • Post-operative nausea and vomiting assessed by postoperative nausea and vomiting score [24 hours postoperatively]

      A simplified risk score for predicting postoperative nausea and vomiting female gender, history of PONV and/or motion sickness, non-smoking status, and postoperative use of opioids. When 0, 1, 2, 3, or 4 factors are present, the risk of postoperative nausea and vomiting is 10%, 20%, 40%, 60%, or 80%, respectively

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • • American Society of Anaesthesiologist (ASA) I-II.

    • Age 18 - 60 years.

    • Elective laparoscopic cholecystectomy.

    • Body Mass Index (BMI) <35 (kg/m2).

    Exclusion Criteria:
    • • Anaphylaxis to local anaesthetics.

    • Anaphylaxis to Neostigmine.

    • American Society of Anaesthesiologist (ASA) III-IV.

    • Chronic pain diseases.

    • Acute cholecystitis.

    • Psychological or nervous system diseases

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sara Farouk Kassem Habib Cairo El Azbakeya Egypt 2222

    Sponsors and Collaborators

    • Kasr El Aini Hospital

    Investigators

    • Principal Investigator: Sara Fa Habib, PhD, Kasr El Aini -Faculty Of Medicine- Cairo University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sara Farouk Kassem Habib, lecturer of anesthesiology, Kasr El Aini Hospital
    ClinicalTrials.gov Identifier:
    NCT04244097
    Other Study ID Numbers:
    • MS-273-2019
    First Posted:
    Jan 28, 2020
    Last Update Posted:
    Sep 3, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 3, 2020